Stathmin 1 and p16INK4A are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma

Gynecologic Oncology

Volumn 139, Issue 1, 2015, Pages 104-111

  Novak, Marián ^a   Lester, Jenny ^b   Karst, Alison M ^a,e   Parkash, Vinita ^c   Hirsch, Michelle S ^d   Crum, Christopher P ^d   Karlan, Beth Y ^b   Drapkin, Ronny ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e ABBVIE INC   (United States)

Author keywords

Fallopian tube; Ovarian; p16; Serous; Stathmin; STIC

Indexed keywords

PROTEIN P16; PROTEIN P53; SMALL INTERFERING RNA; STATHMIN; STATHMIN 1; UNCLASSIFIED DRUG; KI 67 ANTIGEN; P16 PROTEIN, HUMAN; STMN1 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CARCINOMA; CLINICAL ARTICLE; FEMALE; GENE SILENCING; HIGH GRADE SEROUS CARCINOMA; HUMAN; HUMAN CELL; IMMORTALIZED CELL LINE; IMMUNOHISTOCHEMISTRY; MISSENSE MUTATION; MORPHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROUS TUBAL INTRAEPITHELIAL CARCINOMA; UTERINE TUBE; BIOSYNTHESIS; CYSTADENOCARCINOMA; DEFICIENCY; GENETICS; METABOLISM; MUTATION; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE; UTERINE TUBE TUMOR;

BIOMARKERS, TUMOR; CELL LINE, TUMOR; CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MUTATION; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; STATHMIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84943363068     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.07.100     Document Type: Article

References (30)

1. R.J. Kurman Origin and molecular pathogenesis of ovarian high-grade serous carcinoma Ann. Oncol. 24 Suppl. 10 2013 x16 x21
2. C.P. Crum, R. Drapkin, D. Kindelberger, F. Medeiros, A. Miron, and Y. Lee Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer Clin. Med. Res. 5 2007 35 44
3. J.M. Piek, P.J. van Diest, R.P. Zweemer, J.W. Jansen, R.J. Poort-Keesom, F.H. Menko, and et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer J. Pathol. 195 2001 451 456
4. A.L. Gross, R.J. Kurman, R. Vang, IeM. Shih, and K. Visvanathan Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics J. Oncol. 2010 2010 126295
5. A. Saleemuddin, A.K. Folkins, L. Garrett, J. Garber, M.G. Muto, C.P. Crum, and et al. Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations Gynecol. Oncol. 111 2008 226 232
6. M.L. Carcangiu, P. Radice, S. Manoukian, G. Spatti, M. Gobbo, V. Pensotti, and et al. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers Int. J. Gynecol. Pathol. 23 2004 35 40
7. F. Medeiros, M.G. Muto, Y. Lee, J.A. Elvin, M.J. Callahan, C. Feltmate, and et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome Am. J. Surg. Pathol. 30 2006 230 236
8. M.J. Callahan, C.P. Crum, F. Medeiros, D.W. Kindelberger, J.A. Elvin, J.E. Garber, and et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction J. Clin. Oncol. 25 2007 3985 3990
9. E. Kuhn, R.J. Kurman, R. Vang, A.S. Sehdev, G. Han, R. Soslow, and et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma - evidence supporting the clonal relationship of the two lesions J. Pathol. 226 2012 421 426
10. Y. Lee, A. Miron, R. Drapkin, M.R. Nucci, F. Medeiros, A. Saleemuddin, and et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube J. Pathol. 211 2007 26 35
11. I. Cass, A.E. Walts, D. Barbuto, J. Lester, and B. Karlan A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers Gynecol. Oncol. 134 2014 492 497
12. C.B. Powell, E.M. Swisher, I. Cass, J. McLennan, B. Norquist, R.L. Garcia, and et al. Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy Gynecol. Oncol. 129 2013 364 371
13. K. Visvanathan, R. Vang, P. Shaw, A. Gross, R. Soslow, V. Parkash, and et al. Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study Am. J. Surg. Pathol. 35 2011 1766 1775
14. C.B. Powell Clinical management of patients at inherited risk for gynecologic cancer Curr. Opin. Obstet. Gynecol. 27 2015 14 22
15. J.W. Carlson, E.A. Jarboe, D. Kindelberger, M.R. Nucci, M.S. Hirsch, and C.P. Crum Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications Int. J. Gynecol. Pathol. 29 2010 310 314
16. A.M. Karst, K. Levanon, S. Duraisamy, J.F. Liu, M.S. Hirsch, J.L. Hecht, and et al. Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas Gynecol. Oncol. 123 2011 5 12
17. A.S. Sehdev, R.J. Kurman, E. Kuhn, and IeM. Shih Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase Mod. Pathol. 23 2010 844 855
18. C.J. O'Neill, H.A. McBride, L.E. Connolly, M.T. Deavers, A. Malpica, and W.G. McCluggage High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour Histopathology 50 2007 773 779
19. V. Phillips, P. Kelly, and W.G. McCluggage Increased p16 expression in high-grade serous and undifferentiated carcinoma compared with other morphologic types of ovarian carcinoma Int. J. Gynecol. Pathol. 28 2009 179 186
20. A.M. Karst, P.M. Jones, N. Vena, A.H. Ligon, J.F. Liu, M.S. Hirsch, and et al. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers Cancer Res. 74 2014 1141 1152
21. S. Domcke, R. Sinha, D.A. Levine, C. Sander, and N. Schultz Evaluating cell lines as tumour models by comparison of genomic profiles Nat. Commun. 4 2013 2126
22. B. Belletti, and G. Baldassarre Stathmin: a protein with many tasks. New biomarker and potential target in cancer Expert Opin. Ther. Targets 15 2011 1249 1266
23. A.K. Witkiewicz, K.E. Knudsen, A.P. Dicker, and E.S. Knudsen The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments Cell Cycle 10 2011 2497 2503
24. G. Ning, J.G. Bijron, Y. Yamamoto, X. Wang, B.E. Howitt, M. Herfs, and et al. The PAX2-null immunophenotype defines multiple lineages with common expression signatures in benign and neoplastic oviductal epithelium J. Pathol. 234 2014 478 487
25. B. Gerdes, A. Ramaswamy, A. Ziegler, S.A. Lang, M. Kersting, R. Baumann, and et al. p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb Ann. Surg. 235 2002 51 59
26. M. Oren, and V. Rotter Mutant p53 gain-of-function in cancer Cold Spring Harb. Perspect. Biol. 2 2010 a001107
27. S. Masciarelli, G. Fontemaggi, S. Di Agostino, S. Donzelli, E. Carcarino, S. Strano, and et al. Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells Oncogene 33 2014 1601 1608
28. K. Alsop, S. Fereday, C. Meldrum, A. deFazio, C. Emmanuel, J. George, and et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group J. Clin. Oncol. 30 2012 2654 2663
29. A. Antoniou, P.D. Pharoah, S. Narod, H.A. Risch, J.E. Eyfjord, J.L. Hopper, and et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies Am. J. Hum. Genet. 72 2003 1117 1130
30. D. Etemadmoghadam, B.A. Weir, G. Au-Yeung, K. Alsop, G. Mitchell, J. George, and et al. Synthetic lethality between CCNE1 amplification and loss of BRCA1 Proc. Natl. Acad. Sci. U. S. A. 110 2013 19489 19494